Tafalgie Therapeutics at BIO 2025!
We are pleased to announce our presence at BIO Convention 2025, the must-attend event for the biotech industry, under the pavilion of the European Innovation Council (EIC).
As the world’s largest event in biotech, the BIO International Convention 2025 is expected to attract over 20,000 professionals from across the biotech and life sciences industries worldwide.
The convention features more than 120 sessions on a wide range of topics, including AI advancements, digital health, biomanufacturing, gene therapy, oncology, and patient advocacy.
This event offers exclusive networking opportunities for companies to connect with global biotech leaders, government officials, investors, and researchers from both the US and around the world.
The last edition of BIO welcomed 19,608 registrants, over 61,500 partnering meetings, more than 1,500 exhibitors, participation from 68 countries and 150 US and international public officials.
A look back at BIO 2025
We were honored to be invited by the European Innovation Council (EIC) to participate in BIO 2025, the must-attend event for the biotech industry!
Our two Vice Presidents, Aziz Moqrich, Chief Scientific Officer, and Olivier Blin, Chief Medical Officer and Head of Development, represented Tafalgie Therapeutics in Boston from June 16 to 19.
This marked Tafalgie Therapeutics’ first appearance at the BIO Convention, the world’s largest event dedicated to innovation in biotechnology and healthcare. At the European pavilion, we had the pleasure of presenting our scientific research and sharing upcoming clinical milestones in the development of our drug candidates with industry leaders.
We were proud to join an exclusive cohort of startups supported by the EIC through its International Trade Fairs Programme 3.0, showcasing breakthrough solutions in the fields of digital health, therapeutics, medical devices, regenerative medicine, immunology, quantum technologies, and much more.
As part of the program, Olivier Blin was invited to speak on the EIC-hosted panel “Where Will the Next Breakthrough Innovation Come from?,” held on Wednesday, June 18, from 11:30 am to 12:30 pm.
The discussion, moderated by Monika Paule, CEO of Caszyme, explored how emerging technologies are driving the next generation of therapies and transforming care pathways and tools.
Over the course of the four-day event, our Vice Presidents spoke with several dozen stakeholders in the sector, including leading pharmaceutical companies like Eli Lilly and Grünenthal, CROs, investors, and a wide range of service and consulting organizations.
Overall, our stay in Boston was a unique opportunity to engage with other professionals and helped strengthen the international profile of our research.
Many thanks to the EIC for their support, for their trust placed in our mission, and for such a vital platform to collaborate at the heart of the global biotech community!